51
Participants
Start Date
April 30, 2015
Primary Completion Date
May 31, 2017
Study Completion Date
May 31, 2017
S-1/Gemcitabine
Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
National Taiwan University Hospital, Taipei
National Cheng Kung University Hospital, Tainan City
Chang Gung Memorial Hospital, Linkou District
Taipei Veterans General Hospital, Taipei
National Cheng-Kung University Hospital
OTHER
National Taiwan University Hospital
OTHER
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
Chang Gung Memorial Hospital
OTHER
TTY Biopharm
INDUSTRY